Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Short term Debt: 2014

Historic Short term Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 1 years, with Dec 2014 value amounting to $1.0 million.

  • Viridian Therapeutics, Inc.\DE's Short term Debt rose 184.58% to $8.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $8.4 million, marking a year-over-year increase of 184.58%. This contributed to the annual value of $1.0 million for FY2014, which is N/A change from last year.
  • According to the latest figures from FY2014, Viridian Therapeutics, Inc.\DE's Short term Debt is $1.0 million.
  • Viridian Therapeutics, Inc.\DE's Short term Debt's 5-year high stood at $1.0 million during FY2014, with a 5-year trough of $1.0 million in FY2014.
  • Over the past 1 years, Viridian Therapeutics, Inc.\DE's median Short term Debt value was $1.0 million (recorded in 2014), while the average stood at $1.0 million.